Welcome to our dedicated page for Elutia news (Ticker: ELUT), a resource for investors and traders seeking the latest updates and insights on Elutia stock.
Elutia Inc. develops and commercializes drug-eluting biomatrix products designed to improve compatibility between implanted medical devices and patients. Company news commonly covers financial results, product revenue from SimpliDerm and cardiovascular products, and development updates for NXT-41 and NXT-41x biomatrix technologies used in surgical reconstruction and related applications.
Recurring updates also include regulatory-process disclosures, commercial planning for plastic and reconstructive surgery, management presentations, equity compensation actions, and Nasdaq listing-compliance matters for Elutia's Class A common stock. The company's communications often connect its biomatrix platform with implant-based breast reconstruction, post-surgical infection reduction, and broader surgical-support use cases.
Elutia (Nasdaq: ELUT) earned 2026 Great Place to Work Certification, recognizing high-trust culture, sustained engagement, and retention in a regulated, innovation-driven company.
Workforce highlights: women 54% of employees and 62% of leaders, median tenure 6.3 years, half hold advanced degrees, one-third hold doctorates. The release cites prior leadership commercial successes, including an $88 million asset sale and $1.5 billion in products brought to market.
Elutia (Nasdaq: ELUT) reported preliminary Q4 2025 results and corporate updates on its NXT-41x program.
Key items: Q4 net sales ~$3.3M (+16% YoY); sale of BioEnvelope to Boston Scientific for $88M completed October 2025; $26.9M of secured debt repaid in Q4; cash and escrowed proceeds totaled $44.3M at 12/31/2025 (cash on hand ~$36.3M plus $8.0M escrow). Elutia plans an FDA filing for NXT-41 in H1 2026 with potential clearance H2 2026 and anticipates FDA clearance of antibiotic-eluting NXT-41x in H1 2027.
Elutia (Nasdaq: ELUT) will present at the Virtual Global BioInnovation Forum during the JP Morgan Healthcare Conference on Jan 13, 2026 at 10:00 a.m. PT / 1:00 p.m. ET. The company will highlight progress on NXT-41x, a next-generation antibiotic-eluting biomatrix for plastic and reconstructive surgery that builds on Elutia's validated biomatrix platform.
Presentation speakers are Randy Mills, PhD, CEO of Elutia, and Christopher Reid, MD, a plastic surgeon and researcher from UC San Diego Health, who will discuss unmet needs in breast reconstruction, including postoperative infection rates up to 25% and serious complication rates affecting one in three patients. A live and archived webcast will be available in the Investors section at investors.elutia.com.
Elutia (Nasdaq: ELUT) reported Q3 2025 results and closed the sale of its BioEnvelope business to Boston Scientific for $88 million (received $80.3 million at closing on Oct 1, 2025). Proceeds were used to pay off a loan ($27.8M) and fund development of NXT-41x, an antibiotic-eluting biomatrix targeting a ~$1.5B U.S. plastic/reconstructive surgery market. Financials: Q3 net sales were $3.3M (Q3 2024: $3.7M); GAAP gross margin improved to 55.8% (Q3 2024: 48.9%). Cash was $4.7M at Sept 30, 2025, with an additional $8M held in escrow.
Elutia (Nasdaq: ELUT) announced it will release third quarter 2025 financial results after market close on Thursday, November 6, 2025. The company said management will host a conference call and webcast the same day starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time. Participants must register to receive a dial-in number and personalized PIN; registrants can also opt for a dial-out when the call begins.
A live and archived webcast will be available in the company’s Investors section at http://investors.elutia.com/. Attendees are asked to log in about 10 minutes before the scheduled start time.
Elutia (Nasdaq: ELUT) announced that Dr. Randy Mills, President and CEO, will present at the LD Micro Main Event XIX in San Diego on Tuesday, October 21, 2025 at 1:00 p.m. PT (4:00 p.m. ET).
A live webcast will be available and Elutia management will hold 1x1 investor meetings. Institutional investors may schedule meetings via an LD Micro representative or by emailing IR@elutia.com.
Elutia (Nasdaq: ELUT) announced on October 10, 2025 the appointment of Guido J. Neels to its Board of Directors; he will also join the Board's audit committee. Mr. Neels brings >40 years of global medical technology leadership, including roles as Operating Partner at EW Healthcare Partners and former Chief Operating Officer of Guidant. In conjunction with his appointment, W. Matthew Zuga and Maybelle Jordan stepped down from the Board. Management framed the hire as supporting Elutia's strategic transformation after the recent EluPro divestiture and to advance its drug‑eluting biomatrix technology into breast reconstruction.
Elutia (NASDAQ:ELUT) has completed the sale of its BioEnvelope business to Boston Scientific Corporation (NYSE:BSX) for $88 million in cash. The sale includes the EluPro™ and CanGaroo® bioenvelopes product lines.
The company will now focus on developing NXT-41x, a drug-eluting biomatrix targeting breast reconstruction infections post-mastectomy. The product addresses a $1.5 billion U.S. market opportunity, with planned market launch in first half of 2027. Currently, one in three breast reconstruction patients face serious complications, with biologics representing 65% of implant-based costs.
Elutia (Nasdaq: ELUT) has published significant clinical and preclinical data demonstrating the effectiveness of their biologic envelopes for cardiac implantable electronic devices (CIEDs). The HEAL study revealed that patients with ECM envelopes experienced 43% lower overall procedural difficulty, including 46% easier generator mobilization and 41% easier lead mobilization during reoperations.
The research also showed complete eradication of bacterial pathogens, including MRSA, with sustained local antibiotic concentrations for up to two weeks. The company's drug-eluting biomatrix technology combines regenerative ECM with broad-spectrum antibiotics to address both infection control and tissue remodeling, with potential applications in higher-risk procedures like breast reconstruction.
Elutia (Nasdaq: ELUT) has announced the sale of its BioEnvelope business, including EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporation (NYSE: BSX) for $88 million in cash. The transaction is expected to close in Q4 2025.
The deal represents a strategic move that validates Elutia's drug-eluting biologics platform and provides non-dilutive funding for the development of NXT-41, targeting the $1.5 billion U.S. breast reconstruction market. The proceeds will enable Elutia to eliminate outstanding debt, address litigation from its previous Orthobiologics business, and reduce burn rate while focusing on advancing its SimpliDerm franchise.